Nitin Bhawnani: Pap starts at 21
- A pathology explainer tied today’s cervical-screening debate back to the still-common U.S. rule: start Pap testing at 21, not earlier, for average-risk patients. - The crucial nuance is age 30–65, where HPV-based screening now drives decisions: primary HPV is preferred in newer guidance, while cotesting remains acceptable. - That matters because labs use p16 only with H&E morphology, limiting overtreatment while triaging true high-grade disease.
Cervical cancer screening sounds simple until you look at the rulebook. There are age cutoffs, different test types, and one really important pathology caveat that gets flattened online. The basic point is still familiar — Pap testing starts at 21 for average-risk patients in the main U.S. framework. But the part that has actually been moving is what happens after 30, where HPV-based screening has taken center stage and pathology workflows matter more than most patients ever see. (acog.org) ### So does Pap really start at 21? Yes — in the longstanding USPSTF-based approach, average-risk patients ages 21 to 29 get cervical cytology alone every 3 years, and screening is not recommended before 21. ACOG’s 2021 guidance kept that structure, and its April 23, 2026 update said recommendations for ages 21–29 remain the same. That is the piece people mean when they say “Pap starts at 21.” (acog.org) ### Why not start earlier? Because more testing is not always better testing. In younger patients, HPV infections are common and often clear on their own, so screening too early can trigger extra follow-up, colposcopies, and treatment for lesions that would never have become dangerous. That tradeoff is built directly into the screening frameworks — catch real precancer, but avoid creating harm from false alarms and overtreatment. (acog.org) ### What changes after 30? This is where the center of gravity shifts. For ages 30 to 65, the old menu was Pap alone every 3 years, cotesting every 5 years, or primary high-risk HPV testing every 5 years. But newer guidance is leaning harder toward HPV-first screening. The December 10, 2024 USPSTF draft recommends primary high-risk HPV screening every 5 years for ages 30–65, with Pap alone or cotesting still allowed as alternatives. (uspreventiveservicestaskforce.org) ### Is cotesting still “central”? It is still important, but not quite the whole story anymore. Cotesting remains an accepted option for ages 30–65, and lots of real-world workflows still use it. But the newer signal from guideline bodies is that primary HPV testing is becoming the preferred anchor, not cotesti(uspreventiveservicestaskforce.org)atients ages 30–65, while still calling clinician-collected primary HPV every 5 years the preferred approach. (acog.org) ### Where does p16 fit in? p16 is not a free-floating tie-breaker that overrides morphology. In lower anogenital squamous lesions, the CAP-ASCCP LAST framework says any p16-positive area must still meet H&E morphologic criteria for a high-grade lesion before it gets reinterpreted that way. In plain English — p16 helps when the biopsy sits in the gray zone, but the stain does not get to invent HSIL on its own. (documents.cap.org) ### Why is that caveat such a big deal? Because p16 can sharpen diagnosis, but it can also push people toward a more serious label if it is used too loosely. The LAST recommendations were built to standardize this exact problem: use p16 when the differential is truly between precancer and a mimic, and require strong, diffuse “block-positive” staining plus (documents.cap.org)to overtreatment. (documents.cap.org) ### What is the real takeaway here? The clean version is this: “Pap starts at 21” is still broadly right for average-risk patients, but it is not the whole modern screening story. The live change is that HPV-based screening now drives more of the algorithm after 30, and pathology interpretation — especially p16 — still has to stay tethered to what the tiss(documents.cap.org)rly and avoid treating noise like cancer. (acog.org)
